Verification of a Motion Sensor for Evaluating Physical Activity in COPD Patients

Miyamoto, Seiko; Minakata, Yoshiaki; Azuma, Yuichiro; Kawabe, Kazumi; Ono, Hiroya; Yanagimoto, Ryuta; Suruda, Tadatoshi

doi:10.1155/2018/8343705

Cited by 27 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PA is largely affected by weather. On rainy days, PA is significantly reduced in comparison to non-rainy days [70][71][72][73]. The time spent performing PA of ≥2.0 METs and ≥3.0 METs were 145.6 min and 21.3 min, respectively, on non-rainy days and 92.8 min and 11.1 min on rainy days [70].…”

Section: Weathermentioning

confidence: 92%

“…In healthy subjects, the PA on weekend days was significantly different from that on weekdays [78,79], and some investigators recommended the inclusion of data from both weekdays and weekend days [80]. In COPD patients, however, the PA on holidays did not differ from that on weekdays [72,81]. This difference might be attributed to the fact that most healthy subjects were working, while most COPD patients were retired.…”

Section: Holidaysmentioning

confidence: 99%

“…Watz et al [65] reported that a period of 2 to 3 days was sufficient to obtain a reliable measurement of physical activity in GOLD stage IV patients, whereas up to 5 days of measurement was required for patients with GOLD stage I. When we evaluated the minimum number of days required after excluding rainy days and days of special behavior, at least a 3-day measurement was required to obtain reproducibility for both the Actimarker™ (triaxial accelerometer; Panasonic, Osaka, Japan) [70] and the Active Style Pro HJA-750C™ (triaxial accelerometer; Omron Healthcare, Kyoto, Japan) [72].…”

Section: Number Of Valid Days Requiredmentioning

confidence: 99%

See 2 more Smart Citations

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients

Minakata

Sasaki

2020

JCM

Self Cite

View full text Add to dashboard Cite

Increasing physical activity (PA) in patients with chronic obstructive pulmonary disease (COPD) is an important issue, however, the effect of bronchodilators on PA is still controversial. The indicators of PA, as measured by an accelerometer, can easily fluctuate based on several factors, which might cause inconsistent results. In this review, we listed the indicators of PA and the factors influencing the reproducibility of indicators of PA, and reviewed reports in which the effects of bronchodilators on PA were evaluated by an accelerometer. Then, we investigated the association between the processing of influencing factors and the effectiveness of bronchodilators for improving the PA of COPD patients. Fifteen reports were extracted using the PubMed database. In all seven reports in which adjustment was performed for at least two of four influencing factors (non-wear time, data from days with special behavior, environmental factors, and number of valid days required to obtain reproducible data), bronchodilators showed beneficial effects on PA. No adjustment was made for any of these factors in any of the four bronchodilator-ineffective reports. This suggests that the processing of influencing factors to secure reproducibility might affect the results regarding the effectiveness of bronchodilators for improving PA in COPD patients.

show abstract

Section: Weathermentioning

confidence: 92%

Section: Holidaysmentioning

confidence: 99%

Section: Number Of Valid Days Requiredmentioning

confidence: 99%

See 1 more Smart Citation

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients

Minakata

Sasaki

2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ The amount of physical activity and the number of steps in daily living will be quantitatively determined using Active style Pro manufactured and distributed by OMRON Corporation [32]. Prior to the assessment, the rater will check the dosing diary filled out by subjects about rainy weather information.…”

Section: Amyotrophic Lateral Sclerosis Assessment Questionnaire-40mentioning

confidence: 99%

Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial)

Morimoto

Takahashi

Fukushima

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Amyotrophic lateral sclerosis (ALS) is one of intractable neurological diseases, which is an incurable disease. ALS is a progressive disease characterized by muscle atrophy and weakness caused by selective vulnerability of upper and lower motor neurons. In the disease research ever conducted, it has been common to use mouse models carrying mutations in responsible genes for familial ALS as pathological models of ALS. However, there is no model that has reproduced the actual conditions of human spinal cord pathology. Thus, we developed a method of producing human spinal motor neurons using human induced pluripotent stem cells (iPSCs) and an innovative experimental technique for drug screening. As a result, ropinirole hydrochloride was eventually discovered after considering preferable transitivity in the brain, tolerability including adverse reactions, and others. Therefore, we explore the safety, tolerability and efficacy of ropinirole hydrochloride to ALS in this clinical trial. Methods/Design: ROPALS trial is a single-center double-blind randomized parallel group-controlled trial of the safety, tolerability, and efficacy of ropinirole hydrochloride extended-release tablet (Requip CR) at 2mg - 16mg doses in patients with ALS. 20 patients will be recruited as active drug and placebo group. All patients will be able to be on the standard treatment for ALS of riluzole if not changed the dosage. The primary outcome will be safety and tolerability at 24 weeks defined from the date of randomization. Secondary outcome will be the efficacy including the change of ALS Functional Rating Scale-Revised (ALSFRS-R), the change in Combined Assessment of Function and Survival (CAFS), and composite endpoint as a sum of Z-transformed scores on the various clinical items. Noteworthy, we will perform explorative search for drug effect evaluation by using the patients-derived iPSCs to prove this trial concept. Eligible patients will have El Escorial Possible, clinically possible and laboratory-supported, clinically probable, or clinically definite amyotrophic lateral sclerosis with disease duration less than 60 months (inclusive), ALSFRS-R score ≥2 points on all items and age from 20 to 80 years. Discussion: Patient recruitment began in December 2018 and the last patient is expected to complete the trial protocol in November 2020. Trial registration: Current controlled trials UMIN000034954 Protocol version: version 1.1 (Date; 7/Nov/2018) Keywords: Amyotrophic Lateral Sclerosis, Ropinirole hydrochloride, Requip CR, iPSC-drug discovery

show abstract

“…heart failure, diabetes, stroke, pulmonary disease) [4,5]. As such, motion maintenence and rehabilitation has increasingly become a core part of disease management [6][7][8][9]. A crucial factor needed to facilitate motion rehabilitation in medicine is simple and accurate characterization of holistic human motion with real-time feedback.…”

Section: Introductionmentioning

confidence: 99%

Human motion component and envelope characterization via wireless wearable sensors

et al. 2020

View full text Add to dashboard Cite

Background: The characterization of limb biomechanics has broad implications for analyzing and managing motion in aging, sports, and disease. Motion capture videography and on-body wearable sensors are powerful tools for characterizing linear and angular motions of the body, though are often cumbersome, limited in detection, and largely non-portable. Here we examine the feasibility of utilizing an advanced wearable sensor, fabricated with stretchable electronics, to characterize linear and angular movements of the human arm for clinical feedback. A wearable skin-adhesive patch with embedded accelerometer and gyroscope (BioStampRC, MC10 Inc.) was applied to the volar surface of the forearm of healthy volunteers. Arms were extended/flexed for the range of motion of three different regimes: 1) horizontal adduction/abduction 2) flexion/extension 3) vertical abduction. Data were streamed and recorded revealing the signal "pattern" of movement in three separate axes. Additional signal processing and filtering afforded the ability to visualize these motions in each plane of the body; and the 3dimensional motion envelope of the arm. Results: Each of the three motion regimes studied had a distinct patternwith identifiable qualitative and quantitative differences. Integration of all three movement regimes allowed construction of a "motion envelope," defining and quantifying motion (range and shapeincluding the outer perimeter of the extreme of motioni.e. the envelope) of the upper extremity. The linear and rotational motion results from multiple arm motions match measurements taken with videography and benchtop goniometer.Conclusions: A conformal, stretchable electronic motion sensor effectively captures limb motion in multiple degrees of freedom, allowing generation of characteristic signatures which may be readily recorded, stored, and analyzed. Wearable conformal skin adherent sensor patchs allow on-body, mobile, personalized determination of motion and flexibility parameters. These sensors allow motion assessment while mobile, free of a fixed laboratory environment, with utility in the field, home, or hospital. These sensors and mode of analysis hold promise for providing digital "motion biomarkers" of health and disease.

show abstract

Verification of a Motion Sensor for Evaluating Physical Activity in COPD Patients

Cited by 27 publications

References 43 publications

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients

Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial)

Human motion component and envelope characterization via wireless wearable sensors

Contact Info

Product

Resources

About